Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announced today that Stephen T. Wills, the Company's Executive Chairman and Interim Principal Executive Officer, will present at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 17th at 10:30 a.m. Eastern time. The conference is being held at the Westin Grand Central Hotel in New York City. To listen to the presentation, investors may visit the investor relations section of Derma Sciences' website at www.dermasciences.com. An archived audio of the presentation will also be available on Derma Sciences' website for 90 days. About Derma Sciences, Inc. Derma Sciences is a tissue regeneration company focused on patent-protected and proprietary advanced wound and burn care treatments. The Company's lead products include TCC-EZ®, a gold-standard total contact casting system for diabetic foot ulcers, and its MEDIHONEY® product line, the leading brand of honey-based dressings for the management of wounds and burns. It is also engaged in the development and commercialization of novel proprietary regenerative products derived from placental/birth tissues for use in a broad range of clinical applications including the treatment of complex chronic wounds, acute wounds and localized areas of injury or inflammation, in addition to filling soft tissue defects or voids. These products are used in orthopedic, spinal and ocular surgical procedures, among others. The Company also offers a full product line of traditional dressings. For more information, please visit www.dermasciences.com.